Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 04, 2006. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of $53.73 per share, which was used to calculate a decrease in the notional allocation of Ordinary Share ADRs within the retirement plan.
Material Changes
Following a re-valuation of the cash element of the notional investment held in the US Retirement Savings Plan, a decrease in the notional allocation of Ordinary Share ADRs occurred on December 1, 2006. This change affected Dr. R G Greig and S M Bicknell.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. The document is strictly a regulatory notification of a specific transaction under Disclosure Rules 3.1.4R(1)(a).
Investor Verification Points
- Verify the impact of the US Retirement Savings Plan re-valuation on executive compensation.
- Confirm the share price of $53.73 per share as of December 1, 2006.
- Review the specific Disclosure Rules 3.1.4R(1)(a) requirements for this transaction type.